Takeda San Diego, Inc.

Takeda Pharmaceutical Company Limited

Takeda California, Inc.

Andrew John Jennings

Anthony R Gangloff

Jeffrey Alan Stafford

Jason W Brown

Benjamin Jones

Andre A Kiryanov

Phong H Vu

Jerome C Bressi

Xiao-Yi Xiao

Sheldon Cao

Stephen L Gwaltney

Zacharia S Cheruvallath

Mark Sabat

Mingnam Tang

Michael Brennan Wallace

Stephen W Kaldor

Haixia Wang

Robert J Skene

Douglas R Dougan

Clifford D Mol

Alexei Brooun

Haxia Wang

Michelle L Kraus

Marc E Navre

Ellen Y T Chien

Christopher L Caster

Yiqin Wu

Disclosed are compounds of the following formula: in which R, R, R, R, R, R, u, and X are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP)

Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Glucokinase activators

Disclosed are compounds of the following formula: 

Substituted pyrido[2,3-b]pyrazines

Compounds of the following formula are provided for use in inhibiting Poly (ADP-ribose) Polymerase (PARP): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.

Poly (ADP-ribose) polymerase (PARP) inhibitors

Pyrazole and fused pyrazole glucokinase activators

Disclosed are compounds of the following formula: in which R, R, R, R, R, X, and q are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

Substituted derivatives of pyrido[3,2-e][1,4]thiazino[4,3-a]pyrazine and pyrido[3,2-e][1,4]oxazino[4,3-a]pyrazine

Disclosed are compounds of the following formula: in which R, R, R, R, R, R, X, and m are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

Substituted 7,8,9,10-tetrahydro-5H-dipyrido[1,2-a:3',2&#x2032;-e]pyrazin-6(6aH)-ones

Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones

Compounds, pharmaceutical compositions, kits and methods are provided for use with histone deacetylases (HDACs) that comprise a compound of the formulae: wherein the variables are as defined herein.

Histone deacetylase inhibitors

Compounds that may be used to inhibit histone deacetylase having the formulaZ-Q-L-M or Z-L-Mwherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

Provided are crystals relating to Protein kinase B&#x3b1;/AKT1 and its various uses.

Crystallization of protein kinase B&#x3b1;/AKT1

A probe, kit comprising the probe, and methods for using the probe are provided where the probe comprises: 

Probe, assay and kits for detecting 11&#x3b2;-hydroxysteroid dehydrogenase and modulators thereof

Compounds that may be used to inhibit histone deacetylase having the formulaZ-Q-L-M or Z-L-Mwherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0&#x2013;10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

Growing community of inventors

San Diego, CA, United States of America

Andrew John Jennings